Before 1980, no one even knew whether a gene or a micro-organism could be patented. But that year, the Supreme Court ruled they could be1 and the biotechnology industry has never looked back. Indeed, the excitement and promise of the industry grow year to year as more sophisticated tools are developed and more ambitious research programs—such as sequencing the human genome itself—come within our power to accomplish.
At Amster, Rothstein & Ebenstein LLP, we have participated from the start in obtaining suitable protection for our clients’ valuable biotechnology discoveries and inventions:
Developments in life sciences and biotechnology are coming at an ever more rapid rate, many embodying techniques, procedures, or discoveries unimaginable just a few short years ago, such as individually targeted genetic therapies.
The value of these cutting-edge techniques—both to the patients whose lives are aided by them, and to your firm as a reward for developing them—can be very high.
Your biotech IP assets deserve the most thoughtful and sophisticated protection. Talk to us.
1 DIAMOND v. CHAKRABARTY, 447 U.S. 303 (1980)